High-throughput humanized mouse models for evaluation of HIV-1 therapeutics and pathogenesis

Methods in Molecular Biology

Volumn 1354, Issue , 2016, Pages 221-235

  Thomas, Tynisha ^a   Seay, Kieran ^a   Zheng, Jian Hua ^a   Zhang, Cong ^a   Ochsenbauer, Christina ^a   Kappes, John C ^a   Goldstein, Harris ^a  

^a NONE

Author keywords

Antiretroviral treatment; HIV 1; Mouse model

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYCLIN T1; IMMUNOSTIMULATING AGENT; LUCIFERASE; MEDROXYPROGESTERONE ACETATE; METHAMPHETAMINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; CCR5 PROTEIN, HUMAN; CYCLIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOLUMINESCENCE; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUNG; LYMPH NODE; MOUSE; MOUSE MODEL; NOD SCID MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RENILLA RENIFORMIS; SMALL INTESTINE; SPLEEN; SUBSTANCE ABUSE; TRANSGENIC MOUSE; VIRUS ENTRY; VIRUS PATHOGENESIS; ANIMAL; CELL LINE; DRUG EFFECTS; FEMALE; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SCREENING; HIV INFECTIONS; MALE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SCID MOUSE; TRANSGENE; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD4; CELL LINE; CYCLIN T; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; RECEPTORS, CCR5; TRANSFECTION; TRANSGENES;

EID: 84952926946     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3046-3_15     Document Type: Chapter

References (25)

1. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996) Identifi cation of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666
2. Imai K, Asamitsu K, Victoriano AF, Cueno ME, Fujinaga K, Okamoto T (2009) Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells. FEBS J 276:7124–7133
3. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451–462
4. Wimmer J, Fujinaga K, Taube R, Cujec TP, Zhu Y, Peng J, Price DH, Peterlin BM (1999) Interactions between Tat and TAR and human immunodefi ciency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255:182–189
5. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632–1639
6. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer MO, Behnke S, Frey J, Oxenius A, Joller H, Aguzzi A, Manz MG, Speck RF (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A 103:15951–15956
7. Ince WL, Zhang L, Jiang Q, Arrildt K, Su L, Swanstrom R (2010) Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol 84:2740–2752
8. Watanabe S, Ohta S, Yajima M, Terashima K, Ito M, Mugishima H, Fujiwara S, Shimizu K, Honda M, Shimizu N, Yamamoto N (2007) Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodefi ciency virus type 1 pathogenesis. J Virol 81:13259–13264
9. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV (2008) Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 324: 149–165
10. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefi ori DC, Kappes JC, Ochsenbauer C (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1–13
11. Miyawaki A (2007) Bringing bioluminescence into the picture. Nat Methods 4:616–617
12. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC (2002) Emergence of resistant human immunodefi ciency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896–1905
13. Sango K, Joseph A, Patel M, Osiecki K, Dutta M, Goldstein H (2010) Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice. AIDS Res Hum Retrovir 26:735–746
14. Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H (2013) Mice transgenic for CD4-specifi c human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment effi cacy. PLoS One 8:e63537
15. Ochsenbauer C, Kappes JC (2009) New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS 4:418–425
16. Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN (2008) Viral complementation allows HIV-1 replication without integration. Retrovirology 5:60
17. Kutsch O, Benveniste EN, Shaw GM, Levy DN (2002) Direct and quantitative single-cell analysis of human immunodefi ciency virus type 1 reactivation from latency. J Virol 76:8776–8786
18. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A 101:4204–4209
19. Ochiel DO, Ochsenbauer C, Kappes JC, Ghosh M, Fahey JV, Wira CR (2010) Uterine epithelial cell regulation of DC-SIGN expressioninhibits transmitted/founder HIV-1 trans infection by immature dendritic cells. PLoS One 5:e14306
20. Wang X, Ho WZ (2011) Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission. Life Sci 88:972–979
21. Toussi SS, Joseph A, Zheng JH, Dutta M, Santambrogio L, Goldstein H (2009) Short communication: methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retrovir 25:1117–1121
22. Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, Pitisuttithum P, Tappero JW, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K (2009) Factors associated with incarceration and incident human immunodefi ciency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 104:235–242
23. Fidel PL Jr, Wolf NA, KuKuruga MA (1996) T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 64:3793–3799
24. Iijima N, Mattei LM, Iwasaki A (2011) Recruited infl ammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 108:284–289
25. Patterson TL, Semple SJ, Staines H, Lozada R, Orozovich P, Bucardo J, Philbin MM, Pu M, Fraga M, Amaro H, Torre Ade L, Martinez G, Magis-Rodriguez C, Strathdee SA (2008) Prevalence and correlates of HIV infection among female sex workers in 2 Mexico-US border cities. J Infect Dis 197: 728–732